In an unprecedented move to outsmart Alzheimer’s disease, researchers are now recruiting participants as young as 18 for a groundbreaking clinical trial aimed at stopping the disease before it can take root. The international study, led by Washington University School of Medicine in St. Louis, marks the first time scientists have attempted to prevent Alzheimer’s by intervening up to 25 years before symptoms typically appear.
The Primary Prevention Trial focuses on individuals from families with rare genetic mutations that virtually guarantee early-onset Alzheimer’s development, typically striking in their 30s, 40s, or 50s. While the trial targets this specific group, researchers believe the findings could revolutionize prevention strategies for all forms of Alzheimer’s disease.
A Race Against Time
“We have seen tremendous progress in the treatment of Alzheimer disease in the past few years,” says Dr. Eric McDade, professor of neurology and the trial’s principal investigator. “Two amyloid-targeting drugs were shown to slow symptoms of the disease and have now been approved by the Food and Drug Administration as treatments for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.”
The study will test remternetug, an investigational antibody developed by Eli Lilly and Company, designed to either remove or prevent the accumulation of amyloid beta plaques in the brain – a key protein linked to Alzheimer’s development. This build-up begins approximately two decades before memory problems surface, offering a crucial window for intervention.
A Personal Fight
For 24-year-old Hannah Richardson, participation in the trial carries deep personal significance. “My grandfather passed away from Alzheimer’s, and so did his mother and all but one of his brothers,” she shares. “My mom and my uncle have been participating in DIAN trials since I was about 10 years old. My mom was always very open about her diagnosis and how it spurred her advocacy for Alzheimer’s research, and I’ve always known I wanted to follow in her footsteps.”
Innovation in Treatment
The trial introduces a more patient-friendly approach to treatment. Unlike current FDA-approved Alzheimer’s medications that require frequent intravenous infusions, remternetug can be administered via under-the-skin injection once every three months. The study will enroll approximately 240 participants, treating each for two years, with results expected within four to five years.
A Global Effort
The ambitious project has garnered substantial financial backing, with more than $130 million committed from various sources. This includes $98.3 million from the National Institute on Aging, $14 million from the Alzheimer’s Association and GHR Foundation, and significant support from private donors and industry partners.
“This innovative study in this special Alzheimer’s patient population has the potential to significantly impact how we prevent Alzheimer’s disease, saving individuals and families from the anguish of this fatal disease,” notes Maria C. Carrillo, PhD, Alzheimer’s Association chief science officer and medical affairs lead.
As the trial moves forward, it represents more than just a scientific endeavor – it’s a beacon of hope for the nearly 13 million Americans projected to have Alzheimer’s disease by 2050, and countless others worldwide. By targeting the disease’s earliest biological changes, researchers aim to prevent not just its symptoms, but its very emergence.
If you found this piece useful, please consider supporting our work with a small, one-time or monthly donation. Your contribution enables us to continue bringing you accurate, thought-provoking science and medical news that you can trust. Independent reporting takes time, effort, and resources, and your support makes it possible for us to keep exploring the stories that matter to you. Together, we can ensure that important discoveries and developments reach the people who need them most.
